The business in Romania blog writes about the Romanian business landscape, doing business in Romania, investing in Romania business and debating on business issues in Romania. Check this Blog's Policy here.
Sitemap | Feedback | Doing Business in Romania report | Opening a Business in Romania | RSS for this Blog
Thursday, November 04, 2004
Drugmaker Antibiotice Iasi saw its net profits drop in the first nine months of the year by around 13% to 2.35 million euros. Turnover rose 2% to 23.4 million euros.
The main cause for the drop was the raising of the tax levied on drug exporters from the 6% of last year to 25%.
Antibiotice makes more than 7 million euros a year from exports to 35 countries and, according to Nani, accounts for more than 10% of the international Vitamin B12 market. The company expects a full-year turnover of 32.5 million euros, up 10% from 2003, and gross profits of over 4 million euros.
Antibiotice will soon begin an investment of approximately 2.5 million euros aimed mainly at upgrading and retooling its production platform (1.5 million euros) and environmental protection measures ( 0.75 million euros).
Posted by Mihai Botea : 11/04/2004 02:34:00 pm
06/01/2004 - 07/01/2004
Transelectrica's rating raised to BB
Investors in the Construction Sector Are Turning T...
Opposition leader says multibillion dollar contrac...
The biggest mall in Romania
New chairman for HOLCIM
Not a sure winner yet in the US Elections.
Romania relaxes forex regime, leu jumps
NBR reserve reached 10 billion EURO
Medical market to reach 2.2 billion USD
Publications & Media
This website is proud to be designed by Mihai Dragan
I usually listen to THIS kind of music.